Sanofi Pasteur success in Phase III efficacy study of vaccine for Dengue disease
Sanofi Pasteur, the vaccines division of Sanofi has announced that the first of two pivotal Phase III efficacy studies with its Dengue vaccine candidate has achieved its primary clinical endpoint. The efficacy study showed a significant reduction of 56% of Dengue disease cases. Initial safety data are consistent with the good safety profile observed in previous studies. Full analysis of the data will be undertaken in the coming weeks and reviewed by external experts prior to disclosure at an upcoming international scientific congress and publication in a peer-reviewed journal later this year.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins